Trending in biopharma: From developing vaccines for pandemics, to overcoming omic workflow bottlenecks
Watch exclusive interviews with industry experts on the key to vaccine development success, the role of biomaterials in creating drug models, and more
31 Mar 2022
Here, we’ve pulled together a playlist of top interviews from The Scientists' Channel, our independent video platform for scientists and clinical experts around the world to share their work. Take a look at the videos below to learn more about the advantages of T-cell vaccines and how to overcome bottlenecks in omics workflows. Plus, discover the role of bioconjugation and protein services in conjugate vaccine development.
Developing vaccines for pandemics: Why equity and education are key
Dr. Margaret Liu, CEO of PAX Therapeutics, explains how her early research on vaccine development became critical to the COVID-19 pandemic. Dr. Liu also reveals the advantages of T-cell vaccines, explores some of the key learnings from the pandemic, and highlights the critical role of education in overcoming future health crises.
How to overcome omic workflow bottlenecks
Dr. John Wilson, Founder and CEO of ProtiFi, discusses the importance of reproducibility in omic workflows and explains how ProtiFi has been able to help simplify processes from sample collection and preparation, to process control, chromatography, and data analysis in the early detection of disease.
The magic behind conjugate vaccine development
Dr. Andrew Lees, CEO and Scientific Director of Fina Biosolutions, explains how Fina Biosolutions has grown to offer a variety of bioconjugation and protein services in its dedication to the provision of affordable conjugate vaccines.
Advances in biomaterial development
Dr. Mohammad Albanna, CEO and Founder of Humabiologics, discusses his team’s work providing biomaterials for applications such as bioprinting, tissue engineering, and the creation of cancer models for drug screening.
Rare disease: How miniaturized immunoassays are advancing therapeutic development
Mark Dysinger, Associate Director, Bioanalytical Development, Alexion Pharmaceuticals, describes how miniaturized immunoassays benefit the accurate analysis of drug-target engagement.
Discover more biopharma content on The Scientists' Channel including interviews with speakers who took part in the SelectScience Virtual Biopharmaceutical Summit 2021:
- Combating cancer: The incubation technology accelerating CAR-T cell therapy development: Dr. Gerhard Bauer, Professor of Hematology and Oncology and Director of the Good Manufacturing Practice (GMP) laboratory at the UC Davis Institute, highlights his current work on the production of CAR-T cells, powerful therapies that use a patient's own immune cells to treat cancer. Watch video >>
- Developing a whole molecule approach for biopharmaceutical analysis: Dr. John Kellie, Associate Fellow, Bioanalysis, Immunogenicity and Biomarkers, GSK, describes a technique for the quantitation of whole molecule biopharmaceutical candidates using high-resolution mass spectrometry. Watch video >>
Visit The Scientists' Channel to watch new videos and stay up to date on the latest research>>
